In the near future, there will be a high demand for central and peripheral pharmacodynamic markers to monitor LRRK2 kinase activity in clinical trials aiming at evaluating the potential of LRRK2 inhibitors as disease-modifying treatment for Parkinson’s disease. This evidence concerns the gene LRRK2 and Parkinson disease.